Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunotherapy
|
| gptkbp:administeredBy |
gptkb:physician
|
| gptkbp:alsoKnownAs |
N-803
nogapendekin alfa inbakicept |
| gptkbp:approvalYear |
April 2023
|
| gptkbp:approvedBy |
patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:combines |
BCG (Bacillus Calmette-Guérin)
|
| gptkbp:developedBy |
gptkb:ImmunityBio,_Inc.
|
| gptkbp:drugClass |
immunostimulant
|
| https://www.w3.org/2000/01/rdf-schema#label |
Anktiva (N-803)
|
| gptkbp:indication |
non-muscle invasive bladder cancer
|
| gptkbp:mechanismOfAction |
IL-15 superagonist
|
| gptkbp:routeOfAdministration |
intravesical
|
| gptkbp:target |
gptkb:natural_killer_cells
gptkb:CD8+_T_cells |
| gptkbp:bfsParent |
gptkb:ImmunityBio
|
| gptkbp:bfsLayer |
7
|